Tilray's Rescheduling Hopes Fade — Why Cannabis Headwinds Remain Strong

The Big Market Report Take

The initial excitement around potential marijuana rescheduling for companies like Tilray Brands (TLRY) has largely dissipated, and frankly, it's about time. While the DEA's reclassification recommendation was a positive step, the headline reminds us that real regulatory hurdles remain. Investors who jumped in expecting an immediate, transformative shift are now facing the reality that this is a long, drawn-out process. Tilray (TLRY) and its peers still operate under significant federal restrictions, impacting everything from banking to interstate commerce. This isn't a sprint; it's a marathon, and we're barely out of the starting blocks.